Shares in Israel's Teva Pharmaceutical Industries have soared after the results of a clinical study of its Duvakitug drug for the treatment of ulcerative colitis and Crohn's disease met primary goals. Teva and French drug-maker Sanofi announced that the second-phase clinical trial results for the drug showed 'unprecedented results.' Teva's US-listed shares jumped 23 percent.
image sourced from original article at https://www.timesofisrael.com/liveblog_entry/shares-of-israels-teva-jump-23-after-in-development-drugs-unprecedented-results/Original article source: https://www.timesofisrael.com/liveblog_entry/shares-of-israels-teva-jump-23-after-in-development-drugs-unprecedented-results/
Source Id: 2024-12-578673851
